🇺🇸 FDA
Pipeline program

ecallantide 60 mg

DX-88/27

Phase 2 small_molecule terminated

Quick answer

ecallantide 60 mg for ACE Inhibitor Induced Angioedema is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
ACE Inhibitor Induced Angioedema
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials